ArticleFrontiers in bioinformatics2026
A multi-epitope pan-betacoronavirus vaccine construct predicted to induce broad-spectrum and durable immune responses: an immunoinformatics approach.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and evaluation of a multi-epitope subunit vaccine against Salmonella Enteritidis infection.Poultry science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recurrent zoonotic spillovers and continuous antigenic evolution among betacoronaviruses, including SARS-CoV, MERS-CoV, and SARS-CoV-2, highlight the urgent need for a broad-spectrum vaccine capable of eliciting cross-protective immunity. Conventional vaccines, although effective against specific strains, may be limited by antigenic mismatch and waning immunity. This study aimed to design a multi-epitope pan-betacoronavirus vaccine targeting conserved regions within the receptor-binding domain (RBD) using an integrated immunoinformatics and reverse vaccinology framework. Methods: Cytotoxic T-lymphocyte (CTL), helper T-lymphocyte (HTL), and linear B-cell epitopes were predicted and screened for antigenicity, allergenicity, toxicity, and non-homology to host proteins. Selected epitopes were assembled into a 285-amino acid multi-epitope construct using optimized linkers (AAY, GPGPG, EAAAK, and GGGGS) and human β-defensin 3 as an adjuvant. Structural modeling and refinement were performed to generate a three-dimensional vaccine model, followed by molecular docking with a B-cell receptor (BCR) Fab model using ClusPro. Molecular dynamics simulations were conducted to evaluate structural stability, and immune responses were assessed through computational immune simulation. Results: The refined vaccine construct produced a stable structural model with a C-score of -3.60. Molecular docking identified a highly ranked complex from a well-populated cluster (Cluster 1; 49 members) with a Lowest Energy score of -865.9, indicating favorable interface complementarity under the docking scoring function. Molecular dynamics simulation over 100 ns supported the structural integrity and dynamic stability of the complex, with minimal backbone deviation and sustained intermolecular interactions. Immune simulations predicted coordinated humoral and cellular responses following a simulated prime-boost regimen, including increased antibody titers, elevated IL-2 and IFN-γ levels, and sustained memory B- and T-cell populations. The selected epitope set showed an estimated global HLA population coverage of 93.28%. Conclusion: This study identifies a promising
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.